Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
MedCity News4d
Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss
The two main ingredients in this drug cannot be dissolved together, so it must be administered by an injection device with two chambers. Novo Nordisk’s manufacturing capacity for CagriSema is ...
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...
BioSpace10d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
The Boston Globe21d
Weight-loss drugs are about to get a lot better
CagriSema — developed by Novo Nordisk ... Wegovy and Zepbound require weekly injections, and patients often have to contend with side effects that can include nausea, fatigue, vomiting, diarrhea ...